all report title image
  • Published On : Nov 2022
  • Code : CMI5332
  • Industry : Pharmaceutical
  • Pages : 156
  • Formats :

Ependymoma is a type of tumor that can form in the brain or spinal cord. Ependymoma rises from the ependymal cells that line the ventricles of the brain and the center of the spinal cord.  Ependymoma can occur at any age, but most often occurs in children under 5 years of age . Children with ependymoma may experience headaches and seizures.

Global ependymoma drug market is estimated to be valued at US$ 143.0 million in 2022 and is expected to exhibit a CAGR of 4.8%during the forecast period (2022-2030).

Figure 1.Global Ependymoma Drug Market Share (%) in Terms of Value, By Drug Type, 2022

Ependymoma Drug  | Coherent Market Insights

Increasing prevalence of ependymoma is expected to drive the market growth during the forecast period.

Increasing prevalence of ependymoma is expected to drive the global ependymoma drug market growth over the forecast period. For instance, according to data published by American Society of Clinical Oncology in January 2022, ependymoma occurs most often in young children, accounting for about 5% of all childhood brain cancers. Approximately 250 children and teens under the age of 19 in the U.S. would be diagnosed with ependymoma in 2022.

CMI table icon

Ependymoma Drug Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 143.0 Mn
Historical Data for: 2017-2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 4.8% 2030 Value Projection: US$ 208.4 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type: Corticosteroids, Antiseizure Agents, Others
  • By Disease Type: Subependymoma, Myxopapillary Ependymoma, Anaplastic Ependymoma, Classic Ependymomas
  • By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Companies covered:

Fera Pharmaceuticals, Pfizer, Novartis AG, Merck KGaA, Baxter, Cipla Limited, Zydus Cadila, Lupin Pharmaceuticals, Inc., UCB, Inc., APOTEX INC, and Moleculin Biotech, Inc.

Growth Drivers:
  • Increasing prevalence of ependymoma
  • Increasing product approvals for the treatment of ependymoma from regulatory authorities
Restraints & Challenges:
  • Side effects associated with the  ependymoma medication

Figure 2.Global Ependymoma Drug Market Share (%), By Distribution Channel, 2022

Ependymoma Drug  | Coherent Market Insights

Increasing product approvals for the treatment of ependymoma from regulatory authorities are expected to drive the market growth during the forecast period

Increasing product approvals for the treatment of ependymoma which is expected to drive the global ependymoma drug market growth during the forecast period. For instance, in April 2021, Moleculin Biotech, Inc., a clinical stage pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had granted Rare Pediatric Disease Designation (RPD) to its p-STAT3 inhibitor, WP1066, for the treatment of ependymoma.

Global Ependymoma Drug Market– Impact of Coronavirus (COVID-19) Pandemic

The supply of raw materials required for production of pharmaceuticals has been severely disrupted due to the forced quarantine and lack of labor during the COVID-19 pandemic. As the link between regional warehouses is not smooth, transportation of raw materials between regions cannot be carried out successfully. This shortage of raw materials and components has negatively affected the supply chain of the global ependymoma drug  market. Thus, the COVID-19 pandemic is expected to have a negative impact on supply chain of ependymoma drug market. According to an article published by the Exploratory Research in Clinical and Social Pharmacy journal in June 2021, a study was carried out to evaluate the impact of COVID-19 on pharmaceutical systems and supply chain in resource-limited countries in Sub-Saharan countries such as Namibia. This study revealed negative impact on availability and access of essential drugs, sanitation and hygiene products, and antimicrobials. Most pharmaceutical companies and pharmacies in Namibia experienced delayed manufacturing and distribution of drugs, which is attributed to reduced inter-country transportation of pharmaceutical goods and limited in-country capacity to manufacture drugs. For instance, according to a review article published by the European Pharmaceutical Review Journal in November 2020, COVID-19 pandemic has caused major challenges with respect to drug shortages and increased manufacturing costs across the globe. Moreover, the same source stated that COVID-19 pandemic has also led to problems such as stockpiling drugs, transportation delay, and others. Some measures that can be taken to ease the supply of pharmaceuticals during the pandemic include next generation technologies such as digital network platforms designed to work across multiple pharmaceutical enterprises and ensure the timely delivery of drugs to patients across the globe.

Global Ependymoma Drug Market: Restraint

The major factors that hinder growth of the global ependymoma drug market include side effects associated with the medication. Dexamethasone a corticosteroid used in the treatment of ependymoma causes side effects which include upset stomach, stomach irritation, vomiting, headache, dizziness, insomnia, restlessness, depression, anxiety, acne, increased hair growth, easy bruising etc.

Key Players

Key players operating in market include Fera Pharmaceuticals, Pfizer, Novartis AG, Merck KGaA, Baxter, Cipla Limited, Zydus Cadila, Lupin Pharmaceuticals, Inc., UCB, Inc., APOTEX INC, and Moleculin Biotech, Inc.

Ependymoma is a rare type of brain tumour called a glioma. It starts from ependymal cells in the brain or spinal cord. Ependymomas can develop in children and adults. They are soft, grayish, or red tumors which may contain cysts or mineral calcifications. Symptoms of ependymomas depend on whether the tumor is in the brain or the spinal cord. These tumors are divided into four major types, subependymoma, myxopapillary ependymoma, anaplastic ependymoma and classic ependymomas. Symptoms of an ependymoma are related to the location and size of the tumor. In infants, increased head size may be one of the first symptoms. Irritability, sleeplessness, and vomiting may develop as the tumor grows. In older children and adults, nausea, vomiting, and headache are the most common symptoms

Market Dynamics

Key players operating in the global ependymoma drug market are focusing on increasing research and development for ependymoma which is expected to drive the market growth during the forecast period. For instance, in April 2022, Pediatric Brain Tumor Consortium initiated Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients with Recurrent Medulloblastoma and Ependymoma. The study is estimated to be completed in July 30, 2030.  Moreover, increasing research funding for ependymoma is expected to propel growth of the global ependymoma drug market over the forecast period. For instance, in November 2021, a team of scientists led by researchers at the Yale School of Public Health had received a US $13 million grant to investigate the molecular evolution of lower grade gliomas, slow growing but malignant brain tumors that primarily affect young adults.

 Key features of the study:

  • This report provides an in-depth analysis of the global ependymoma drug market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global ependymoma drug market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
  • Key companies covered as a part of this study include Fera Pharmaceuticals, Pfizer, Novartis AG, Merck KGaA, Baxter, Cipla Limited, Zydus Cadila, Lupin Pharmaceuticals, Inc., UCB, Inc., APOTEX INC, and Moleculin Biotech, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global ependymoma drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global ependymoma drug market

Detailed Segmentation:

  • Global Ependymoma Drug Market, By Drug Type:
    • Corticosteroids
    • Antiseizure Agents
    • Others
  • Global Ependymoma Drug Market, By Disease Type :
    • Subependymoma
    • Myxopapillary Ependymoma
    • Anaplastic Ependymoma
    • Classic Ependymomas
  • Global Ependymoma Drug Market, By Distribution Channel :
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
  • Global Ependymoma Drug Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Fera Pharmaceuticals *
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Pfizer .
    • Novartis AG
    •  Merck KGaA
    •  Baxter
    •  Cipla Limited
    •  Zydus Cadila
    •  Lupin Pharmaceuticals, Inc.,
    •  UCB, Inc.,
    • APOTEX INC,
    • Moleculin Biotech, Inc

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The Global Ependymoma Drug Market size is estimated to be valued at US$ 143.0 million in 2022 and is expected to exhibit a CAGR of 4.8% between 2022 and 2030.
Factors such as increasing prevalence of ependymoma and increasing product approvals for the treatment of ependymoma from regulatory authorities are expected to drive the market growth over the forecast period.
Antiseizure agents segment is expected to hold a major market share during the forecast period.
The major factors hampering growth of the market include side effects associated with the medication.
Major players operating in the market are Fera Pharmaceuticals, Pfizer, Novartis AG, Merck KGaA, Baxter, Cipla Limited, Zydus Cadila, Lupin Pharmaceuticals, Inc., UCB, Inc., APOTEX INC, and Moleculin Biotech, Inc.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo